Long-Term Outcomes of Patients with Squamous Cell Carcinoma of the Temporal Bone after Concomitant Chemoradiotherapy

Abstract

This article aims to clarify the long-term outcomes of patients with squamous cell carcinoma of the temporal bone who underwent concomitant chemoradiotherapy (CCRT). The study design was a retrospective chart review. From December 2001 to June 2014, 23 patients with cancer of the temporal bone who were treated by CCRT at the Tohoku University Hospital and the Iwate Medical University Hospital were enrolled in this study. For advanced cancer of the temporal bone, a modified docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen was used for CCRT. The long-term outcomes, including prognoses and late complications, were analyzed after CCRT of patients with cancers of the temporal bone. The main long-term complications were stenosis of the external auditory canal and conductive hearing loss. No harmful late complications were observed in these patients. Disease-specific survival rates were 84.9% for all patients, 100% for patients of stage I, II, and III ( = 10), and 75.5% for patients of stage IV ( = 13) at 5 years. Our study showed that CCRT is an effective treatment choice for squamous cell carcinoma of the temporal bone. Furthermore, CCRT using the TPF regimen is a safe and effective initial treatment for patients with advanced cancers of the temporal bone.

Long‐term survival after immunotherapy for uncontrolled locally advanced temporal bone squamous cell carcinoma followed by chemoradiotherapy: A case report

“…For locally advanced disease (T3/4), a multimodal approach involving surgery followed by adjuvant radiotherapy and chemotherapy is the mainstay of treatment. Emerging evidence suggests that concurrent chemoradiotherapy may achieve outcomes comparable to those of surgery combined with adjuvant radiotherapy 13,14 . In a meta-analysis conducted by Krystelle et al 9 , no significant difference was observed in the 5-year survival rates between patients with T1/T2 TBSCC who underwent radical surgical resection and those who received radiotherapy alone (100% vs. 81.3%, P = 0.103).…”

“…For locally advanced disease (T3/4), a multimodal approach involving surgery followed by adjuvant radiotherapy and chemotherapy is the mainstay of treatment. Emerging evidence suggests that concurrent chemoradiotherapy may achieve outcomes comparable to those of surgery combined with adjuvant radiotherapy 13,14 . In a meta‐analysis conducted by Krystelle et al 9 ,.…”

Analysis of Prognostic Factors For External Auditory Canal Carcinoma: A 22‐Year Experience

“…Previously, radical RT alone has been reported to be insufficient for any stage of EAC SCC, which led to advocacy for primary treatment with surgery 16,17 . More recently in comparison with the standard of care (surgery with adjuvant RT), definitive CRT has been demonstrated in T3‐T4 tumors to yield equivalent OS rates 18–21 . However, due to lack of quality evidence from prospective randomized trials, guidelines on treatment options are not standardized.…”

“…16,17 More recently in comparison with the standard of care (surgery with adjuvant RT), definitive CRT has been demonstrated in T3-T4 tumors to yield equivalent OS rates. [18][19][20][21] However, due to lack of quality evidence from prospective randomized trials, guidelines on treatment options are not standardized.…”